gvtcx

National Framework Agreement for Aseptically Prepared Cytotoxic Medicines and Monoclonal Antibodies - East of England, London and South East Coast

NHS England Published 18 Sept 2019 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£36,000,000
Statuscomplete
Category (CPV) 85149000
RegionEast of England, London, South East
Deadline9 Mar 2020
Contract start1 Jul 2020
Contract end30 Jun 2021
Procedureopen
SME suitableYes
OCIDocds-b5fd17-525d0f3b-5857-4690-bd86-5c4afd034691

Awards (3)

This procurement was awarded to 3 suppliers. Values shown are per-award; the notice total is £36,000,000.

SupplierValueDateStatus
Baxter Healthcare Ltd shared £36,000,000 11 Jun 2020 active
ITH Pharma Ltd shared £36,000,000 11 Jun 2020 active
Qualasept Ltd (trading as Bath ASU) shared £36,000,000 11 Jun 2020 active

description

NHS framework agreement to supply aseptically prepared cytotoxic medicines and monoclonal antibodies - East of England, London and South East Coast. The framework may also be used by private sector contractors and agents working on behalf of the above. The framework agreement will commence on 1.7.2020 for a period of 12 months, with options to extend for a further 36 months.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
10 Jul 2020 Award (award) · 7d9e1c27-c941-4992-ae28-c6a2ccd8c447-369712

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.